Corbus Pharmaceuticals Holdings, Inc. (CRBP)
D
Pipeline Grade
Financial Position (from SEC Filings)
$26.1M
Cash & Equivalents
$25.6M
Quarterly Burn Rate
3 mo
Est. Cash Runway
$179M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (0 Assets)
No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.
Upcoming Catalysts
| Date | Event | Drug |
|---|---|---|
| 2026-11-01 | Phase2 Readout | — |
| 2027-01-16 | Phase2 Readout | — |
Active Clinical Trials (3)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT06603844 | First-in-human Study of CRB-601-01 to Treat Patients With Advanced Solid Tumor. | PHASE2 | Recruiting | 156 |
| NCT06265727 | A Phase 1/2 Study to Investigate CRB-701 in Solid Tumors | PHASE2 | Recruiting | 348 |
| NCT07310901 | A 2-part, Phase 1b Clinical Study Designed to Evaluate the Safety, PK, and Efficacy of CRB-913 in Participants With Obes... | PHASE1 | Active Not Recruiting | 252 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.